To test if PASMC proliferation induced under the two-hit conditions is responsive to treatment with PAH-relevant drugs, Ambrisentan, an FDA-approved selective antagonist of ET-1 receptor A and AZD5153, a compound from a structural class of BET inhibitors, were added to the flow system. The gene discussed is DNER; the disease is pulmonary arterial hypertension.